AT-406 (SM-406): Orally Bioavailable IAP Inhibitor for Cancer Research

Executive Summary: AT-406 (SM-406) is a small-molecule, orally bioavailable inhibitor of apoptosis proteins (IAPs), notably antagonizing XIAP, cIAP1, and cIAP2 with nanomolar affinity (APExBIO, product page). It induces the degradation of cIAP1 and activates apoptotic pathways in cancer cells, resulting in caspase-3, -7, and -9 activation and tumor cell death (Zhang et al. 2011, DOI). AT-406 sensitizes ovarian cancer cells to carboplatin and shows in vivo efficacy in mouse xenograft models, inhibiting tumor progression and prolonging survival. The compound displays favorable oral bioavailability across species and is well tolerated in clinical studies at doses up to 900 mg. This article provides a structured, evidence-based overview for translational and preclinical researchers targeting apoptosis pathways in oncology.

Biological Rationale

Inhibitor of apoptosis proteins (IAPs) are a conserved family of endogenous regulators that inhibit caspases and suppress programmed cell death. XIAP, cIAP1, and cIAP2 are the primary human IAPs involved in modulating apoptosis, cell division, and cell cycle progression (APExBIO). These proteins contain baculoviral IAP repeat (BIR) domains that bind and inhibit caspases-3, -7, and -9, directly blocking apoptosis in cancer cells (Zhang 2011). Overexpression of IAPs is frequently observed in diverse malignancies, correlating with resistance to chemotherapy and poor clinical outcomes (Zhang 2011). Pharmacological antagonism of IAPs restores apoptosis, sensitizes tumor cells to cytotoxic agents, and provides a mechanistic rationale for targeted cancer therapy.

Mechanism of Action of AT-406 (SM-406)

AT-406 (SM-406) is a non-peptidic, small-molecule antagonist designed to target multiple IAPs. It binds to the BIR3 domain of XIAP with a Ki of 66.4 nM, cIAP1 with a Ki of 1.9 nM, and cIAP2 with a Ki of 5.1 nM, displacing endogenous caspase substrates and reactivating apoptotic signaling (APExBIO). Upon binding, AT-406 triggers rapid proteasomal degradation of cIAP1, reducing its cellular abundance within hours of treatment. The resulting loss of IAP-mediated caspase inhibition leads to activation of effector caspases (3 and 7) and initiator caspase-9, culminating in programmed cell death. AT-406's activity is independent of p53 status and operates in both intrinsic and extrinsic apoptosis pathways (Beyond Apoptosis: Next-Generation IAP Inhibition...). This distinguishes AT-406 from single-target or peptide-based IAP antagonists, offering broader utility in diverse cancer contexts. This mechanism also complements CRISPR-based screens identifying apoptotic pathway vulnerabilities in cancer cells (Torelli 2024).

Evidence & Benchmarks

• AT-406 binds XIAP BIR3 (Ki: 66.4 nM), cIAP1 (Ki: 1.9 nM), and cIAP2 (Ki: 5.1 nM) in vitro, validated by fluorescence polarization assays (APExBIO).
• AT-406 induces rapid (≤ 2 hours) proteasomal degradation of cIAP1 protein in cancer cell lines, as shown by immunoblotting (Zhang 2011).
• Human ovarian cancer cells treated with AT-406 display IC₅₀ values of 0.05–0.5 μg/mL for growth inhibition; treatment duration: 24–72 hours (Zhang 2011).
• Combination with carboplatin results in synergistic cell death in ovarian cancer models, measured by caspase-3/7 activity and cell viability assays (Zhang 2011).
• Oral dosing in mice (10–100 mg/kg) achieves plasma concentrations sufficient to inhibit tumor growth in ovarian and breast cancer xenografts (Zhang 2011).
• AT-406 is well tolerated in early-phase clinical studies, with dose-limiting toxicity not observed up to 900 mg oral dosing (Zhang 2011).
• CRISPR-based functional genomics screens confirm that IAPs are non-redundant apoptosis regulators in mammalian cells, and small-molecule IAP antagonists like AT-406 are effective in modulating cell fate (Torelli 2024).

This article extends the scope of 'AT-406 (SM-406): Orally Bioavailable IAP Inhibitor for Ca...' by providing mechanistic and workflow guidance for new users, and updates 'AT-406 (SM-406): Precision IAP Inhibition for Cancer Rese...' with recent CRISPR-based evidence and best practices for combinatorial approaches. For broader strategic insights, see 'Beyond Apoptosis: Next-Generation IAP Inhibition...', which discusses clinical translation and future directions.

Applications, Limits & Misconceptions

AT-406 is primarily used in research applications involving modulation of apoptosis in cancer biology. Its broad-spectrum IAP antagonism is valuable in preclinical drug screening, combination therapy (e.g., with platinum-based agents), and studies of apoptosis signaling networks. The compound is not indicated for use in non-cancerous models where IAPs play essential roles in normal cell survival and immune homeostasis. AT-406 should be used with caution in experiments involving primary immune cells, as IAP inhibition can trigger off-target cell death. For mechanistic studies of host-pathogen interactions, such as Toxoplasma gondii infection, IAP antagonism provides a tool for dissecting apoptosis-driven immune responses, as supported by recent in vivo CRISPR screens (Torelli 2024).

Common Pitfalls or Misconceptions

• AT-406 is not selective for a single IAP: It antagonizes XIAP, cIAP1, and cIAP2; applications requiring single-target specificity may require alternative strategies.
• Not suitable for water-based formulations: AT-406 is insoluble in water; use DMSO or ethanol (≥27.65 mg/mL) as solvent for in vitro and in vivo studies (APExBIO).
• Short-term solution stability: DMSO or ethanol solutions should be freshly prepared and used promptly; long-term storage reduces compound integrity.
• Not a direct caspase activator: AT-406 functions by relieving IAP-mediated inhibition, not by directly activating caspase enzymes.
• Not a pan-cancer cure: AT-406's efficacy is context-dependent and is not universally effective across all tumor types or in the absence of functional apoptotic machinery.

Workflow Integration & Parameters

For in vitro studies, AT-406 is typically used at concentrations of 0.1–3 μM in cancer cell lines for 24 hours to evaluate apoptosis induction and caspase activation (APExBIO). For in vivo studies, oral administration (10–100 mg/kg) in mice achieves target plasma levels for IAP inhibition and tumor growth suppression (Zhang 2011). The compound is a solid (MW: 561.71) and must be properly dissolved in DMSO or ethanol. Storage at -20°C is recommended, and all solutions should be freshly prepared. For combinatorial studies, AT-406 can be administered concurrently with DNA-damaging agents such as carboplatin to assess synergy. Researchers should monitor cell viability, caspase activity, and target protein degradation as primary endpoints. Refer to the official A3019 kit documentation for detailed protocol guidance.

Conclusion & Outlook

AT-406 (SM-406) sets a benchmark for orally bioavailable, multi-target IAP inhibition in cancer research. Its robust in vitro and in vivo efficacy, coupled with favorable pharmacokinetics and tolerability, enables precise interrogation of apoptosis pathways in preclinical and translational models. Future research will further clarify its role in combination regimens and in modulating immune responses to both malignant and infectious challenges. For the latest mechanistic and clinical updates, consult APExBIO and the referenced literature.